A coalition of leading pharmaceutical companies
Initiative Pharma was founded by major industry players, including Guerbet, Ipsen, LFB, Pierre Fabre, Sanofi, Servier and Théa.
The alliance has already expanded with Chiesi, SERB Pharmaceuticals and France Biotech.
A strategic ambition: innovation and sovereignty
Initiative Pharma aims to promote a strong industrial vision focused on:
- pharmaceutical innovation
- investment in France
- production relocation
- improved access to medicines
During the press conference, Ivan Perrichon highlighted the importance of an agile organization focused on key industry priorities.
Théa’s commitment to innovation
Théa’s strategy reflects these ambitions:
- €150 million invested in France by 2030
- 12% of revenue dedicated to research and development
This investment focuses on ophthalmology, a field in which France remains internationally competitive.
A challenging landscape
Despite increased awareness following the COVID-19 crisis, several indicators remain concerning:
- France has dropped from first to fifth place in pharmaceutical production in Europe over the past decade
- 40% of medicines approved at the European level are not available in France
These figures highlight structural challenges within the sector.
Driving industrial transformation
Initiative Pharma aims to address these issues by promoting a unified industrial voice. Its president, Charles Wolf, calls for:
- reinventing the industry
- strengthening health independence
- building a unified industrial strategy
The video recap of the press conference provides a comprehensive overview of the announcements and strategic priorities shaping the future of the pharmaceutical industry in France.